Clinical Trials Browser

Phase 1/2 × Active not recruiting × regorafenib × Clear all

NCT05672316 2026-01-28

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

Phase 1/2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04781192 2026-01-23

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

Phase 1/2 Active not recruiting

Gastrointestinal

Advanced Biliary Tract Cancer

NCT03657641 2025-07-04

Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms